While it remains to be seen how the drug pricing provisions imposed by the IRA will affect the broader pharmaceutical industry, several pharmaceutical manufacturers and other industry stakeholders have challenged the law, including through lawsuits brought against the DHHS, the Secretary of the DHHS, CMS, and the CMS Administrator challenging the constitutionality and administrative implementation of the IRA’s drug price negotiation provisions.
All entries for: Rigel Pharmaceuticals Inc
November 4, 2025
Rigel Pharmaceuticals Inc
Neutral Outlook
South San Francisco, CA
51-200 employees
Since the May 12, 2025 MFN executive order, the Trump administration has continued to exert pressure on drug manufacturers to implement MFN pricing, and in early October 2025 announced two agreements with Pfizer and AstraZeneca. The Trump administration also announced that both manufacturers would make products available at significant discounts on a new direct-to-consumer website that will be launched in January 2026. Further, the current administration has suggested that it may impose tariffs on pharmaceuticals if similar MFN agreements are not reached with other drug manufacturers.
August 5, 2025
Rigel Pharmaceuticals Inc
Neutral Outlook
South San Francisco, CA
51-200 employees
The current presidential administration has also signaled its intent to pursue healthcare reform measures, including those aimed at reducing prescription drug prices. For example, President Trump has signed multiple executive orders addressing prescription drug pricing and access, including: on April 15, 2025, outlining several actions the Secretary of the DHHS must take to optimize healthcare regulations that will provide access to prescription drugs at lower costs; on May 5, 2025, aiming to promote domestic production of critical medicines; and on May 12, 2025, aiming to establish a “most favored nation” drug pricing policy that would tie US drug prices to the prices paid for drugs in other countries. Further, the current administration has suggested that it may impose tariffs on pharmaceuticals